Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluer effektiviteten og sikkerheden af ​​LivPhcD-kapsler i NAFLD-emner

29. september 2026 opdateret af: TCM Biotech International Corp.

Multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse for at evaluere effektiviteten og sikkerheden af ​​LivPhcD-kapsler i NAFLD-emner

Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.

There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.

LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

110

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Not Required For This Country
      • Taipei, Not Required For This Country, Taiwan, 221
        • National Taiwan University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female between 20 and 75 years of age.
  2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
  3. Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
  4. CAP ≥ 238 db/m
  5. Fibro scan (transient elastography) F0~F3

Exclusion Criteria:

  1. Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
  2. Type 1 diabetes mellitus.
  3. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
  4. Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
  5. Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
  6. Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
  7. Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
  8. Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
  9. Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
  10. Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
  11. Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
  12. History of HIV

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Placebo without active ingredient

Placebo matching LivPhcD cap.

Aktiv komparator: 2 cap.LivPhcD/per day

515mg/LivPhcD cap. 2 cap./per day

2 caps. LivPhcD cap. after meal, once a day

Aktiv komparator: 4 cap.LivPhcD/per day

515mg/LivPhcD cap. 4 cap./per day, BID

4 caps. LivPhcD cap. after meal, BID

Aktiv komparator: 6 cap.LivPhcD/per day

515mg/LivPhcD cap. 6 cap./per day, TID

6 caps. LivPhcD cap. after meal, TID

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Reduction of Liver Fat
Tidsramme: 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter)

36 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in liver fat at least 30% reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change of liver fat by CAP

24 weeks and 36 weeks
Stable in liver fat
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fibrosis at least 10% reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Stable in liver fibrosis
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change of FIB-4

24 weeks and 36 weeks
Change in ALT
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of ALT

24 weeks and 36 weeks
Change in AST
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AST

24 weeks and 36 weeks
Change in GGT
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of GGT

24 weeks and 36 weeks
Change in AP
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AP

24 weeks and 36 weeks
Change in Bilirubin
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Bilirubin

24 weeks and 36 weeks
Change in Triglyceride
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Triglyceride

24 weeks and 36 weeks
Change in Total Cholesterol
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Total Cholesterol

24 weeks and 36 weeks
Change in HDL-C
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of HDL-C

24 weeks and 36 weeks
Change in LDL-C
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of LDL-C

24 weeks and 36 weeks
Change in TNF-α
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of TNF-α

24 weeks and 36 weeks
Change in C-Reactive Protein
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of C-Reactive Protein

24 weeks and 36 weeks
Change in Albumin
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Albumin

24 weeks and 36 weeks
Occurrence of adverse events and serious adverse events
Tidsramme: 24 weeks and 36 weeks

Between group difference in the occurrence of adverse events and serious adverse events.

24 weeks and 36 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. december 2023

Primær færdiggørelse (Faktiske)

22. december 2025

Studieafslutning (Faktiske)

22. januar 2026

Datoer for studieregistrering

Først indsendt

28. maj 2023

Først indsendt, der opfyldte QC-kriterier

25. juni 2023

Først opslået (Faktiske)

5. juli 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • LivPhcD-001

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .